{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06649331","nct_id":"NCT06649331","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06649331. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"SHR-A1811 (HER2 ADC)","label":"A","type":"EXPERIMENTAL"},{"description":"SHR-A1921 (TROP2 ADC)","label":"B","type":"EXPERIMENTAL"},{"description":"SHR-A2009 (HER3 ADC)","label":"C","type":"EXPERIMENTAL"},{"description":"SHR-A2102 (Nectin4 ADC)","label":"D","type":"EXPERIMENTAL"},{"description":"SHR-A1811 (HER2 ADC) and Famitinib (VEGFR inhibitor)","label":"E","type":"EXPERIMENTAL"},{"description":"SHR-A1811 (HER2 ADC) and Fat Module Formula for Special Medical Purposes (for Medium-Chain Triglyceride Supplementation)","label":"F","type":"EXPERIMENTAL"},{"description":"9MW2821 (Nectin4 ADC)","label":"G","type":"EXPERIMENTAL"},{"description":"9MW2821 (Nectin4 ADC) + trastuzumab","label":"H","type":"EXPERIMENTAL"},{"description":"Disitamab Vedotin (RC48)","label":"I","type":"EXPERIMENTAL"},{"description":"Treatment of physician's choice (TPC)","label":"J","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-09","type":"ESTIMATED"},"conditions":["Advanced Breast Cancer","Metastatic Breast Cancer","Triple Negative Breast Cancer (TNBC)","HER2-negative Breast Cancer","Breast Cancer"],"enrollment":{"count":160,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SHR-A1811","otherNames":[],"type":"DRUG"},{"name":"SHR-A1921","otherNames":[],"type":"DRUG"},{"name":"SHR-A2009","otherNames":[],"type":"DRUG"},{"name":"SHR-A2102","otherNames":[],"type":"DRUG"},{"name":"Famitinib","otherNames":[],"type":"DRUG"},{"name":"Fat Module Formula for Special Medical Purposes","otherNames":[],"type":"DIETARY_SUPPLEMENT"},{"name":"Trastuzumab (or biosimilar)","otherNames":[],"type":"DRUG"},{"name":"9MW2821","otherNames":[],"type":"DRUG"},{"name":"Disitamab Vedotin (RC48)","otherNames":[],"type":"DRUG"},{"name":"Treatment of physician's choice (TPC)","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"Fudan University","official_title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate (ORR)","timeFrame":"The observation period related to this endpoint is up to 36 months."}],"references":[],"start_date":{"date":"2024-10-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06649331"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06649331"}